Revelation Biosciences is a life sciences company whose development of immunologic-based therapies is based on the well-established biology of phosphorylated hexaacyl disaccharide (PHAD) and its effect on the innate immune system. The company begins the year with outstanding test results, preparing for an FDA decision, presenting its results before a prestigious group and preparing for commercialization. We believe investors should look at the stock now as we approach an inflection point.
